TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03192865

Intervention type: PROCEDURE
Intervention: diaphragmatic assessment using ultrasounds.
Description: A diaphragmatic assessment will be performed using ultrasound. This is a pain free assessment. This assessment is commun in our unit after arthroscopic shoulder surgery.

Intervention type: PROCEDURE
Intervention: diaphragmatic assessment using ultrasounds.
Description: A diaphragmatic assessment will be performed using ultrasound. This is a pain free assessment. This assessment is commun in our unit after arthroscopic shoulder surgery.
Study: NCT02964949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban
Description: Edoxaban will be provided in blister packs with active and placebo tablets maintaining the blind, i.e., one 60 mg active tablet and a 15 mg placebo or one 60 mg active tablet and a 15 mg active tablet. Transition doses of 30 mg + 15 mg edoxaban are provided in 14-tablet blister packs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Edoxaban will be provided in blister packs with active and placebo tablets maintaining the blind, i.e., one 60 mg active tablet and a 15 mg placebo or one 60 mg active tablet and a 15 mg active tablet. Transition doses of 30 mg + 15 mg edoxaban are provided in 14-tablet blister packs.
Study: NCT04188301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVM w/ ALB
Description: Participants will be given a single dose of oral IVM (150 µg/kg) plus ALB (400 mg) (IVM/ALB)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of IDA
Description: Participants will be given a single dose of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Three daily doses of IDA
Description: Participants will be given one daily dose for 3 days of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)
Study: NCT01163448

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy
Description: A baseline DCE-MRI will be obtained prior to the day of radiotherapy treatment. Immediately following the delivery of radiotherapy another DCE-MRI will be performed to assess for perfusion changes in the prostate resulting from irradiation. RP will be completed within 6 weeks (+ 2 weeks) of radiation and the RP specimen will be assessed for radiation treatment effect and other pathologic parameters (including surgical margin status) by a dedicated genitourinary pathologist. Following RP, participants will follow-up with their surgeon every 3 months for one year, with visits alternating between the urologist and the radiation oncologist. After the first year follow-up will occur at 6 month intervals until the patient is 3 years out from surgery.
Study: NCT01685073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem extended-release
Description: nightly administration of zolpidem extended-release
Study: NCT03555877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25mg once daily as indicated in the SmPC
Study: NCT02217904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg islatravir
Description: Single oral dose of 1 mg islatravir administered following ≥8 hour fast
Study: NCT03555877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: (prefilled syringes with fulvestrant 250mg each), 500mg given once a month, with an additional 500mg dose given two weeks after the first dose as indicated in the SmPC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: (prefilled syringes with fulvestrant 250mg each), 500mg given once a month, with an additional 500mg dose given two weeks after the first dose as indicated in the SmPC
Study: NCT01430572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Starting dose: 5.0 mg by mouth on Days 1 - 5 of Cycle 1. On Day 7 and every cycle-day with an odd number, only everolimus will be administered.~Dose Expansion Phase: Maximum tolerated dose (MTD) from lead in phase.
Study: NCT03007121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine intrathecal
Description: Administration of intrathecal injection of 0.3 mg preservative-free morphine in 3 ml NS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine + Sufentanil epidural
Description: Continuous epidural infusion of a mixture containing in 1 ml bupivacaine 0,125% and sufentanil 0,4 mcg at 8 ml/h.
Study: NCT02796469

Intervention type: DRUG
Intervention: Placebo
Study: NCT00606489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caldolor
Description: 800 milligrams of intravenous ibuprofen (patients greater 12 years of age) or 10 milligrams/kilograms (patients greater than 12 years; maximum of 400 milligrams) every 6 hours
Study: NCT03007121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine intravenous
Description: Patiernt-controlled i.v. analgesia with morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine intravenous
Description: Patiernt-controlled i.v. analgesia with morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine intravenous
Description: Patiernt-controlled i.v. analgesia with morphine
Study: NCT00671216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705
Description: Subjects will receive 200 (mcg) microgram once daily as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705
Description: Subjects will receive 200 (mcg) microgram once daily as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705
Description: Subjects will receive 200 (mcg) microgram once daily as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705
Description: Subjects will receive 200 (mcg) microgram once daily as a single dose
Study: NCT02217904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg islatravir
Description: Single oral dose of 2 mg islatravir administered following ≥8 hour fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg islatravir
Description: Single oral dose of 10 mg islatravir administered following ≥8 hour fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg islatravir
Description: Single oral dose of 30 mg islatravir administered following ≥8 hour fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg islatravir
Description: Single oral dose of 30 mg islatravir administered following ≥8 hour fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg islatravir
Description: Single oral dose of 0.5 mg islatravir administered following ≥8 hour fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25 mg islatravir
Description: Single oral dose of 0.25 mg islatravir administered following ≥8 hour fast
Study: NCT00589667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus Gemcitabine
Description: Patients will receive pemetrexed (500 mg/m2 IV infusion over approximately 10 minutes) followed immediately by gemcitabine (1250 mg/m2 IV infusion given over approximately 30 minutes) on day 1 and day 15 of a 28-day cycle. Vitamin supplementation will be as follows: Vitamin B12: 1000 µg IM injection no less than 1 week prior to the first dose of pemetrexed, and continuing approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.~Folic acid: The preferred oral daily dose of folic acid is 350 to 1000 µg. Daily folate supplementation begins no less than 1 week prior to the first dose of pemetrexed and continues until 3 weeks after the last dose of pemetrexed.~For rash prophylaxis, dexamethasone (4 mg po twice per day) should be taken on the day before, the day of, and the day after each dose of pemetrexed unless clinical contraindications exist.
Study: NCT00606489

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03480984

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Programmed Intermittent Bolus
Description: 6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via an hourly programmed bolus

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Infusion
Description: 6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via continuous infusion
Study: NCT01587248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harmonic
Description: Dissection with harmonic scalpel

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: electrocautery
Description: Dissection in modified radical mastectomy
Study: NCT03242226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: two spectacles
Description: single-vision spectacles for distant vision, and +3.00ADD spectacle for near vision

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: single vision spectacles
Description: Wear single vision spectacle only
Study: NCT03776084

Intervention type: DEVICE
Intervention: Continuous Positive Airway Pressure
Description: CPAP indication
Study: NCT01983007

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Description: Performance of high-intensity exercise

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise
Description: Performance of low-intensity exercise
Study: NCT03765047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Arm
Description: The physical activity intervention consists of:~1. School Engagement and Assessment - Based on the customized assessment, training is provided for school staff to develop the capacity to increase PA. A school PA team is established.~2. Training - School teams are provided with ongoing in-person and virtual training to learn strategies for increasing PA before and during the school day. A training summit meeting will occur each summer, starting with the summer prior to the intervention. Teams will create a weekly calendar of activities to increase PA time to a minimum of 40 mts/day.~3. PA Equipment and Resources - After training, schools are provided with PA equipment, resources and teaching aids to facilitate the integration of PA into the school day.~4. Ongoing Assessment and Technical Assistance - Student accelerometer data will allow for monitoring of PA levels, so that additional technical assistance for classroom teachers can be provided if needed
Study: NCT04793516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR Therapy Game
Description: Participants will complete 15 sessions of VR-based therapy modules developed for use in helping people with spatial neglect. These 15 sessions will be completed over 4-5 weeks.
Study: NCT01479647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Tablet, 1 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Tablet, 1 mg, single dose
Study: NCT04480229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telenursing and Counseling
Description: After the first face-to-face training, counseling on the phone was conducted every week for four cycles of chemotherapy treatment. In total, six counseling sessions and four face-to-face training sessions were conducted for each patient.
Study: NCT00896012

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney Biopsy
Description: Skin over the kidney will be cleansed and disinfected. The skin and deeper tissue will be numbed with novocaine like solution. A special needle will be inserted guided by ultrasound into the kidney for an instant to withdraw the small specimen.
Study: NCT01479647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Tablet, 10 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Tablet, 10 mg, single dose
Study: NCT00671216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: Subjects will receive 50 mcg once daily as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: Subjects will receive 50 mcg once daily as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: Subjects will receive 50 mcg once daily as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: Subjects will receive 50 mcg once daily as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705 and GW642444
Description: Subjects will receive combination of GSK233705 200 mcg and GW642444 50 mcg as a single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705 and GW642444
Description: Subjects will receive combination of GSK233705 200 mcg and GW642444 50 mcg as a single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705 and GW642444
Description: Subjects will receive combination of GSK233705 200 mcg and GW642444 50 mcg as a single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705 and GW642444
Description: Subjects will receive combination of GSK233705 200 mcg and GW642444 50 mcg as a single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching study medication will be inhaled by subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching study medication will be inhaled by subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching study medication will be inhaled by subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching study medication will be inhaled by subjects
Study: NCT04258865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348 F1
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348 F1
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348 F1
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348 F1
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348 F1
Description: QD, PO
Study: NCT03860350

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aged Garlic Extract
Study: NCT04258865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348 F1
Description: QD, PO
Study: NCT00896012

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney Biopsy
Description: Skin over the kidney will be cleansed and disinfected. The skin and deeper tissue will be numbed with novocaine like solution. A special needle will be inserted guided by ultrasound into the kidney for an instant to withdraw the small specimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamune (sirolimus/rapamycin)
Description: Rapamune will be given at a dose of 5mg/day for two days beginning at the initiation of tacrolimus reduction. Thereafter, Rapamune will be given at a dose of 3 mg/day. The dose of Rapamune will be titrated to achieve a blood level (by HPLC) between 5 and 10 for the duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Patients in this group will continue to receive tacrolimus at reduced doses. Doses will be titrated to achieve tacrolimus trough blood levels between 4 and 6. Myfortic at doses of 720 mg BID and steroids will be continued for the duration of the study (12 months).
Study: NCT01932788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 4000 IU in gummy form
Description: Subjects randomized to the Vitamin D3 4000 IU gummy vitamin arm, the investigational drug, will consume 4 gummies/day beginning at 10-14 weeks of your pregnancy. All subjects will consume a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of your pregnancy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gummy vitamin
Description: Subjects randomized to receive placebo, also in gummy form but manufactured without Vitamin D3, will consume 4 gummies/day beginning at 10-14 weeks of pregnancy. All subjects will take a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of pregnancy.
Study: NCT03654144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest
Description: oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined Oral Contraceptive
Description: oral tablets
Study: NCT04039529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCENERGY-guided Biopsy
Description: Use of SCENERGY during a lung, liver or kidney biopsy
Study: NCT02253043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (Beijing PINS Medical Co., Ltd)
Description: PINS Stimulator System
Study: NCT03381118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 500-1000 mg/m2 bid IV infusion on D-4, -3, -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 40 mg IV infusion on D+5
Study: NCT03860350

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02005224

Intervention type: OTHER
Group type: OTHER
Intervention: LCHF diet and a bout of exercise
Description: Low-carbohydrate/high-fat diet; effect on insulin sensitivity, lipid profile, weight and body composition. Participants ingested LCHF diet for three weeks before undergoing an oral glucose tolerance test. The same afternoon the participated in an one hour indoor bicycle training at 75% at HFpeak. The following morning they underwent a new oral glucose tolerance test. Body composition and weight were measured before and after the intervention. Oral glucose tolerance test was also performed before the intervention for baseline. Blood samples were collected before and after the intervention for lipid profile analyses.
Study: NCT03722914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzonatate 200 mg
Description: 200 mg/pellet, 1pellet/time, 3times/day
Study: NCT04258865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348 F2
Description: QD, PO
Study: NCT03722914

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: blank control 0mg
Description: 0 mg/pellet, 1pellet/time, 3times/day
Study: NCT03827668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833 alone
Description: In Period 1, Days 1-5, participants will receive PF-06650833 once daily alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 alone
Description: In Period 2, Days 1-7, participants will receive PF-06651600 once daily alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833 together with PF-06651600
Description: In Period 2, Days 8-12, participants will receive PF-06650833 once daily together with PF-06650833 once daily.
Study: NCT04191603

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MONOPOLAR HOOC
Description: COLPOTOMY WITH MONOPOLAR HOOC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PLASMAKINETIC BIPOLAR SPATULA
Description: COLPOTOMY WITH BIPOLAR SPATULA
Study: NCT04682353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-46046
Description: SC injection of 300 mg/mL (120 mg/0.4mL; 180 mg/0.6mL; 240 mg/0.8mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-46046
Description: SC injection of 300 mg/mL (120 mg/0.4mL; 180 mg/0.6mL; 240 mg/0.8mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-46046
Description: SC injection of 300 mg/mL (120 mg/0.4mL; 180 mg/0.6mL; 240 mg/0.8mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo-subQ Provera
Description: SC injection of 104 mg/0.65 mL
Study: NCT03381118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 500-1000 mg/m2 bid IV infusion on D+1, +2, +3
Study: NCT04007913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: teleCBIT
Description: Eight sessions of individual behavior therapy
Study: NCT00418379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 IR (4M)
Description: 300 IR grass pollen allergen extract tablet starting 4 months before the pollen season

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 IR (2M)
Description: 300 IR grass pollen allergen extract tablet starting 2 months before the pollen season

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT00954837

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fine needle aspiration
Description: Classical needle biopsy techniques will be used, with patients lying on their backs with their necks in hyperextension. An initial ultrasound scan will be used to determine the site or sites at which the needle should be inserted. Following extensive disinfection of the skin of the neck, the needle will be inserted under ultrasound guidance. The needle will be moved gently backwards and forwards and displaced radially in a clockwise direction to recover cellular material by capillarity. In general, several (two or three) passages of the needle are required for a given nodule. It is possible to carry out FNA on up to three nodules in a single session. For each passage, a new, sterile, single-use needle will be used. The insertion of each needle will be preceded by an ultrasound scan.
Study: NCT04344379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxychloroquine
Description: 200 mg BID per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Description: 250 mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hydroxychloroquine placebo
Description: 200 mg BID per day
Study: NCT04258865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348 F2
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348 F2
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348 F2
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348 F2
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PO
Study: NCT01479647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Tablet, 24 mg, single dose
Study: NCT02479906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep TMS System
Description: Deep TMS treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: Sham treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions